PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma

Pancreas Cancer Clinical Trial

— PaCaReg  

Official title:

PaCaReg: A Multicenter Registry Trial for the Assessement of Clinical, Epidemiological and Biological Profiles in Patients With Pancreatic Ductal Adenocarcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04099134
• Other study ID #: PaCaReg
• Status: Recruiting
• Start date: October 10, 2018
• Est. completion date: October 2029

Study information

• Verified date: September 2019
• Source: University of Ulm
• Contact: Thomas Seufferlein, MD
• Phone: +49 731 50044501
• Email: thomas.seufferlein[@]uniklinik-ulm.de
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

PaCaReg is a multicenter registry trial aiming in the assessement of clinical, epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. completion date: October 2029
• Est. primary completion date: October 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Treatment naive histologically or cytologically proven pancreatic ductal adenocarcinoma (PDAC) or highly suspicious diagnosis (only pre-curative-intended resection)

• Age =>18 years

• written informed consent

Exclusion Criteria:

• papillary cancer

• neuroendocrine pancreatic tumors

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreas Adenocarcinoma
• Pancreas Cancer
• Pancreatic Neoplasms

Locations

Country	Name	City	State
Germany	Universitätsklinikum Ulm	Ulm

Sponsors (1)

Lead Sponsor	Collaborator
University of Ulm

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	General assessment of applied therapy modalities in pancreatic cancer		First diagnose to death or end of surveillance (5 years after curative resection)
Primary	Quality of life in pancreatic cancer patients	EORTC QLQ c30 and PAN 26	First diagnose to death or end of surveillance (5 years after curative resection)
Secondary	General epidemiologic assessment	Epidemiologic questionaire	First diagnose to death or end of surveillance (5 years after curative resection)
Secondary	Assessment of tumor surveillance in pancreatic cancer patients		First diagnose to death or end of surveillance (5 years after curative resection)
Secondary	Evaluation of predictive and prognostic markers		First diagnose to death or end of surveillance (5 years after curative resection)